Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting

On November 3, 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting from December 3-6 in San Diego (Press release, Hoffmann-La Roche , NOV 3, 2016, View Source [SID1234516214]). The abstracts include more than 20 oral presentations across a broad range of medicines and combinations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth of data we are presenting at ASH (Free ASH Whitepaper) this year reflects our deep commitment to people with blood diseases," said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development. "We are excited to share the results of the pivotal GALLIUM study in previously untreated follicular lymphoma, which showed that people treated with Gazyva/Gazyvaro plus chemotherapy lived significantly longer without their disease worsening than those treated with Rituxan/MabThera plus chemotherapy."

The results from the phase III GALLIUM study have been selected for presentation during the Plenary Scientific Session, which honours the top six abstracts submitted to the meeting, as determined by the ASH (Free ASH Whitepaper) Program Committee. Results from other studies of Gazyva/Gazyvaro1 will also be presented at the meeting, including an overall survival update from the phase III GADOLIN study in Rituxan/MabThera2 -refractory indolent (slow-growing) non-Hodgkin lymphoma (NHL) and the first results from the phase III GOYA study in previously untreated diffuse large B-cell lymphoma (DLBCL).

Updated results from the phase III SABRINA study comparing subcutaneous and intravenous Rituxan/MabThera in previously untreated follicular lymphoma will be presented. The US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the subcutaneous formulation of Rituxan, with an action date of June 26, 2017.

Early results will be shared for combinations of Venclexta/Venclyxto with either Gazyva/Gazyvaro or Rituxan/MabThera in chronic lymphocytic leukaemia and certain types of non-Hodgkin lymphoma. Further follow-up from early studies in multiple myeloma and acute myeloid leukaemia that support further investigation of Venclexta/Venclyxto in these diseases will also be presented. Venclexta/Venclyxto is being co-developed by AbbVie and Roche.

The first cohort from a non-interventional study of people with haemophilia will be presented, including real world safety and efficacy data from patients with inhibitors to factor VIII replacement therapy treated with current standard of care according to routine clinical practice. Separately, there are currently three pivotal studies underway to explore the safety and efficacy of emicizumab3 in the treatment of haemophilia A: a phase III study in people 12 years of age or older with haemophilia A with factor VIII inhibitors investigating weekly dosing; a phase III study in people younger than 12 years of age with factor VIII inhibitors investigating weekly dosing; and a phase III study in people 12 years of age or older without factor VIII inhibitors investigating weekly and every other week dosing.

Key abstracts featuring Roche medicines that will be presented at ASH (Free ASH Whitepaper) can be found in the table below.
Follow Roche on Twitter via @Roche and keep up to date with ASH (Free ASH Whitepaper) Annual Meeting news and updates by using the hashtag #ASH16.
Overview of key presentations featuring Roche medicines at ASH (Free ASH Whitepaper) 2016
Medicine Abstract title Abstract number/Presentation details
Gazyva/Gazyvaro
(investigational use) Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study
#6 (Plenary Scientific Session)
04 Dec 2016
2.00–4.00pm PT
Minimal Residual Disease Assessment in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab as First-Line Induction Immunochemotherapy in the Phase III GALLIUM Study
#613 (Oral presentation)
05 Dec 2016
7.00am PT
(7.00–8.30am PT)
Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results From an Open Label, Randomized Phase 3 Study (GOYA)
#470 (Oral presentation)
04 Dec 2016
4.45pm PT
(4.30–6.00pm PT)
Gazyva/Gazyvaro
(approved use, updated study results) Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Prolongs Overall Survival Compared With Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study
#615 (Oral presentation)
05 Dec 2016
7.30am PT
(7.00–8.30am PT)
Rituxan/MabThera (subcutaneous formulation)
Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of The Phase III SABRINA Study
#1103 (Oral presentation)
05 Dec 2016
5.30pm PT
(4.30–6.00pm PT)
Venclexta/Venclyxto
(investigational use) Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) And Coexisting Medical Conditions: Final Results of The Run-In Phase of the Randomized CLL14 Trial
#2054 (Poster)
03 Dec 2016
5.30-7.30pm PT
Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-cell Non-Hodgkin Lymphoma (CAVALLI)
#3032 (Poster)
04 Dec 2016
6.00-8.00pm PT
Phase 2 Study of Venetoclax plus Rituximab or Randomized Venetoclax plus Bendamustine+Rituximab (BR) versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data (CONTRALTO)
#617 (Oral presentation)
05 Dec 2016
8.00am PT
(7.00-8.30am PT)
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia (M14-387)
#2843 (Oral presentation)
03 Dec. 2016
10:45am PT
(9.30- 11.00am PT)
Emicizumab
(investigational) Bleeding Events and Safety Outcomes in Patients with Hemophilia A with Inhibitors: A Prospective, Multicenter, Non-Interventional Study
#3800 (Poster)
05 Dec 2016
6.00-8.00pm PT